Kronos Bio Revenue and Competitors

Location

$278M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Kronos Bio's estimated annual revenue is currently $19.7M per year.(i)
  • Kronos Bio's estimated revenue per employee is $182,269
  • Kronos Bio's total funding is $278M.
  • Kronos Bio's current valuation is $601.8M. (January 2022)

Employee Data

  • Kronos Bio has 108 Employees.(i)
  • Kronos Bio grew their employee count by 8% last year.

Kronos Bio's People

NameTitleEmail/Phone
1
Sr. VP, BiologyReveal Email/Phone
2
Executive Director Business DevelopmentReveal Email/Phone
3
SVP, Drug DiscoveryReveal Email/Phone
4
VP Portfolio, Program Management and Commercial strategyReveal Email/Phone
5
VP, Assistant General CounselReveal Email/Phone
6
Chief Scientific OfficerReveal Email/Phone
7
Senior Director, Corporate AdministrationReveal Email/Phone
8
Director, Clinical Data Management and ProgrammingReveal Email/Phone
9
Director Computational BiologyReveal Email/Phone
10
DirectorReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$4.4M57-8%$53MN/A
#2
$21.2M137-26%$110MN/A
#3
$0.9M60%N/AN/A
#4
$2.3M1515%N/AN/A
#5
$1.6M10-17%N/AN/A
#6
$0.7M950%N/AN/A
#7
$11.5M74-12%N/AN/A
#8
$0.4M27510%$236.7MN/A
#9
$4M51-74%$160MN/A
#10
$2.3M1515%N/AN/A
Add Company

What Is Kronos Bio?

Kronos Bio, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics designed to transform patient outcomes by targeting dysregulated transcription.

keywords:N/A

$278M

Total Funding

108

Number of Employees

$19.7M

Revenue (est)

8%

Employee Growth %

$601.8M

Valuation

N/A

Accelerator

Kronos Bio News

2022-04-17 - KRONOS BIO, INC. : Other Events, Financial Statements and Exhibits (form 8-K)

Item 5.02 Other Events. On April 20, 2022 , the Compensation Committee of the Board of Directors of. Kronos Bio, Inc. (the "Company")...

2022-04-13 - Comparing Clovis Oncology (NASDAQ:CLVS) & Kronos Bio ...

This table compares Clovis Oncology and Kronos Bio's revenue, earnings per share and valuation. Gross Revenue, Price/Sales Ratio, Net Income...

2022-04-06 - Kronos Bio Presents Preclinical Data on Oral CDK9 Inhibitor ...

Kronos Bio continues to enroll patients in Phase 1/2 clinical trial, with additional data anticipated in Q4 2022.

2020-08-25 - Kronos Bio Raises $155 Million In Private Financing

Kronos Bio announced private financing of about $155 million of convertible notes with $148 million in funding received to date and the remaining $7 million to be funded by mid-September pursuant to binding commitments Kronos Bio – a private clinical-stage biopharmaceutical company dedicated to ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
N/A10864%N/A
#2
$15.7M1087%N/A
#3
$29.7M110-9%N/A
#4
$16M1105%$73M
#5
$22.2M110-9%$160.8M